List of Figures
Figure 1: Global Sales Forecast by Country for PAH in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in PAH During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of PAH During the Forecast Period
Figure 4: Target Pathways of the Currently Marketed Drugs for PAH
Figure 5: 7MM, Diagnosed Incidence of PAH (Cases per 100,000 Population), Both Sexes, All Ages, 2019
Figure 6: 7MM, Diagnosed Prevalence of PAH (%), Both Sexes, All Ages, 2019
Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of PAH
Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PAH by NYHA Functional Classes
Figure 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PAH by Comorbidities: CTD, PH, CHD, and COPD
Figure 10: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PAH by Comorbidities: Scleroderma, Diabetes
Figure 11: 7MM, Diagnosed Incident Cases of PAH, N, Both Sexes, All Ages, 2019
Figure 12: 7MM, Diagnosed Incident Cases of PAH, N, by Sex, All Ages, 2019
Figure 13: 7MM, Diagnosed Incident Cases of PAH by Age, N, Both Sexes, 2019
Figure 14: 7MM, Diagnosed Prevalent Cases of PAH, N, Both Sexes, All Ages, 2019
Figure 15: 7MM, Diagnosed Prevalent Cases of PAH, N, by Sex, All Ages, 2019
Figure 16: 7MM, Diagnosed Prevalent Cases of PAH by Age, N, Both Sexes, 2019
Figure 17: 7MM, Diagnosed Prevalent Cases of PAH by NYHA Functional Classes, N, Both Sexes, All Ages, 2019
Figure 18: Diagnostic Approach to PAH
Figure 19: Unmet Needs and Opportunities in PAH
Figure 20: Overview of the Development Pipeline in Pulmonary Arterial Hypertension
Figure 21: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PAH in the 7MM During the Forecast Period
Figure 22: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of PAH During the Forecast Period
Figure 23: Analysis of the Company Portfolio Gap in PAH During the Forecast Period
Figure 24: Global (7MM) Sales Forecast by Country for PAH in 2019 and 2029
Figure 25: Sales Forecast by Class for PAH in the US in 2019 and 2029


List of Tables
Table 1: PAH: Key Metrics in the 7MM
Table 2: NYHA/WHO Functional Class (FC)
Table 3: Risk Factors and Comorbidities for PAH
Table 4: Diagnosed Prevalent Cases of PAH by Comorbidities, N, Both Sexes, All Ages, 2019
Table 5: Treatment Guidelines for PAH
Table 6: Country Profile - US
Table 7: Country Profile - 5EU
Table 8: Country Profile - Japan
Table 9: Leading Treatments for PAH, 2020
Table 10: United Therapeutics’ Disease Portfolio Assessment, 2020
Table 11: GSK’s Disease Portfolio Assessment, 2020
Table 12: Actelion’s Disease Portfolio Assessment, 2020
Table 13: Steady Therapeutics’ Disease Portfolio Assessment, 2020
Table 14: Acceleron Pharma’s Disease Portfolio Assessment, 2020
Table 15: Apeiron Biologics’ Disease Portfolio Assessment, 2020
Table 16: Northern Therapeutics’ Disease Portfolio Assessment, 2020
Table 17: PhaseBio Pharmaceuticals’ Disease Portfolio Assessment, 2020
Table 18: Liquidia Technologies’ Disease Portfolio Assessment, 2020
Table 19: Mezzion Pharma’s Disease Portfolio Assessment, 2020
Table 20: PAH Market - Global Drivers and Barriers, 2019-2029
Table 21: Key Events Impacting Sales for PAH in the US, 2019-2029
Table 22: PAH Market - Drivers and Barriers in the US, 2019-2029
Table 23: Key Events Impacting Sales for PAH in the 5EU, 2019-2029
Table 24: PAH Market - Drivers and Barriers in the 5EU, 2019-2029
Table 25: Key Events Impacting Sales for PAH in Japan, 2019-2029
Table 26: PAH Market - Global Drivers and Barriers in Japan, 2019-2029
Table 27: Key Historical and Projected Launch Dates for PAH
Table 28 summarizes the key historical and projected patent expiry dates for PAH across the 7MM.
Table 29: Key Historical and Projected Patent Expiry Dates for PAH
Table 30: High-Prescribing Physicians (non-KOLs) Surveyed, By Country